Clinical trial · Interventional
A Photodynamic Therapy for Treatment of Actinic Keratoses
NCT00558688CI-TRIAL-00055377completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to compare the efficacy of photodynamic therapy with 5-aminolevulinic acid and intense pulsed light vs absence of treatment for actinic keratoses.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Actinic Keratoses | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Photodynamic therapy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- 1
- description
- Light Therapy
- interventionNames
- Procedure: Photodynamic therapy
- type
- EXPERIMENTAL
- label
- 2
- description
- Light Therapy
- interventionNames
- Procedure: Photodynamic therapy
Primary outcomes (1)
- measure
- Visual assessment of lesions
- timeFrame
- 4 weeks
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: Age greater than or equal to 18 years * Have a t least 4 nonhypertrophic AK lesions on the body * The subjects are in good health * The subject has the willingness and the ability to understand and provide informed consent for the use of their tissue and communicate to the investigator Exclusion Criteria: * Subjects who are pregnant or lactating * Subjects with a history of cutaneous photosensitivity or porphyria, hypersensitivity to porphyrins, or photodermatosis * Subjects with use of photosensitizing drugs within 1 week of study start * Subjects with use of topical medications such as corticosteroids, alpha-hydroxyacids or retinoids 2 weeks before study entry * Subjects with systemic steroid therapy within 4 weeks before study entry * Subjects who received previous treatment of target AKs * Subjects with systemic treatment with chemotherapeutic agents, masoprocol (Actinex), immunotherapy, or retinoids within 2 months of study entry * Subjects with prior history of hypersensitivity reactions to lidocaine * Subjects who are unable to understand the protocol or to give informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.